Wikipedia

User:Mr. Ibrahem/Dalbavancin

< User:Mr. Ibrahem
Mr. Ibrahem/Dalbavancin
Clinical data
Trade namesDalvance, Xydalba, Zeven, other
AHFS/Drugs.comMonograph
MedlinePlusa614036
License data
Routes of
administration		Intravenous
Legal status
Legal status
Identifiers
  • 2-deoxy-1-O-[(3S,15R,18R,34R,35S,38S,48R,50aR)-5,31-dichloro-38-{[3-(dimethylamino)propyl]carbamoyl}-6,11,34,40,44-pentahydroxy-42-(α-D-mannopyranosyloxy)-15-(methylamino)-2,16,36,50,51,59-hexaoxo-2,3,16,17,18,19,35,36,37,38,48,49,50,50a-tetradecahydro-1H,15H,34H-20,23:30,33-dietheno-3,18:35,48-bis(iminomethano) 4,8:10,14:25,28:43,47-tetrametheno[1,14,6,22]dioxadiazacyclooctacosino[4,5-m][10,2,16]benzoxadiazacyclohexacosin-56-yl]-2-[(10-methylundecanoyl)amino]-β-D-glucopyranuronic acid [1]
Chemical and physical data
FormulaC88H100Cl2N10O28
Molar mass1816.71 g·mol−1
3D model (JSmol)
  • CC(C)CCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1Oc2c3cc4cc2Oc5ccc(cc5Cl)[C@H]([C@H]6C(=O)N[C@@H](c7cc(cc(c7-c8cc(ccc8O)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]9c1cc(cc(c1Cl)O)Oc1ccc(cc1O)[C@H](C(=O)N[C@H](Cc1ccc(cc1)O3)C(=O)N9)NC)O[C@@H]1[C@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O)C(=O)NCCCN(C)C)O)C(=O)O)O)O
  • InChI=1S/C88H100Cl2N10O28/c1-38(2)13-10-8-6-7-9-11-14-61(106)94-70-73(109)75(111)78(86(120)121)128-87(70)127-77-58-31-43-32-59(77)124-55-23-19-42(29-50(55)89)71(107)69-85(119)98-67(80(114)92-25-12-26-100(4)5)48-33-44(102)34-57(125-88-76(112)74(110)72(108)60(37-101)126-88)62(48)47-28-40(17-22-52(47)103)65(82(116)99-69)95-83(117)66(43)96-84(118)68-49-35-46(36-54(105)63(49)90)123-56-24-18-41(30-53(56)104)64(91-3)81(115)93-51(79(113)97-68)27-39-15-20-45(122-58)21-16-39/h15-24,28-36,38,51,60,64-76,78,87-88,91,101-105,107-112H,6-14,25-27,37H2,1-5H3,(H,92,114)(H,93,115)(H,94,106)(H,95,117)(H,96,118)(H,97,113)(H,98,119)(H,99,116)(H,120,121)/t51-,60-,64-,65-,66-,67+,68+,69+,70-,71-,72-,73-,74+,75+,76+,78+,87-,88+/m1/s1 ☒N
  • Key:IZJRUXNZMRDQJI-SZUNQUCBSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Dalbavancin, sold under the trade names Dalvance among others, is an antibiotic used to treat bacterial skin infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).[2] It is give by injection into a vein either as a single dose or two doses one week apart.[2][3]

Common side effects include nausea, diarrhea, rash, and headache.[2] Other side effects may include antibiotic associated colitis, constipation, and low white blood cells.[3] It is unclear if use is safe in pregnancy or breastfeeding.[4] It is in the lipoglycopeptide class of medications, along with vancomycin.[2]

Dalbavancin was approved for medical use in the United States in 2014 and Europe in 2015.[2][5] In the United States the a course of medication costs about 4,800 USD as of 2021.[6] In the United Kingdom this amount costs the NHS about £1,700.[3]

References edit

  1. ^ European Medicines Agency (EMA) assessment of Dalbavancin http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002840/WC500183871.pdf Archived 2018-06-19 at the Wayback Machine
  2. ^ a b c d e "Dalbavancin Monograph for Professionals". Drugs.com. Archived from the original on 5 March 2021. Retrieved 21 July 2021.
  3. ^ a b c BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 561. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  4. ^ "Dalbavancin (Dalvance) Use During Pregnancy". Drugs.com. Archived from the original on 28 November 2020. Retrieved 21 July 2021.
  5. ^ "Xydalba". Archived from the original on 20 January 2021. Retrieved 21 July 2021.
  6. ^ "Dalbavancin Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 21 July 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Dalbavancin&oldid=1207943515"